Cyclin-dependent kinase 2 (CDK2)

Where the papers sit

14 papers from the last 6 months study Cyclin-dependent kinase 2 (CDK2) directly · updated from PubMed 10 Oct 2026

• In Silico Anticancer Screening

  Computational screening is being used to find CDK2-directed and multitarget anticancer candidates, especially for breast and lung cancer. Molecular docking, dynamics simulations and network pharmacology recur across compound and phytochemical studies. The work increasingly combines predicted target networks with drug-like properties and Cytochrome P450 (CYP) liabilities. Experimental validation remains the main open step, since most evidence is still computational.

  6 papers · 42.9%

• Cancer Cell-Cycle Signaling

  CDK2-linked cell-cycle signaling is being connected to transcriptional control, proliferation and immunotherapy response in cancer. Cyclin E-CDK2 regulation of BRD4 and the cancer-cell transcriptional program is a recurring mechanistic theme. Other studies place CDK2 within PTEN/AKT/p53 signaling or pursue dual EGFR/CDK2 inhibitors. The field is moving toward combining pathway biology with antiproliferative drug discovery, but therapeutic selectivity and in vivo benefit remain open.

  5 papers · 35.7%

• Others — Selective CDK2 Inhibition

  CDK2 drug discovery is moving beyond conventional inhibition toward selective protein degradation and noncanonical recruiter design. Molecular dynamics and mechanistic pharmacokinetic studies are being used to improve inhibitor selectivity and exposure. CDK6, retinoblastoma and Cereblon (CRBN) recur as relevant considerations in defining activity and degradation mechanisms. The wound-dressing study is unrelated to this therapeutic focus, making the cluster only partly coherent.

  3 papers · 21.4%